McKesson Corporation Reports Fiscal 2026 Third Quarter Results and Raises Full Year Adjusted EPS Guidance




McKesson Corporation Reports Fiscal 2026 Third Quarter Results and Raises Full Year Adjusted EPS Guidance

IRVING, Texas–(BUSINESS WIRE)–McKesson Corporation (NYSE: MCK) has released its fiscal 2026 third quarter financial results. Results can be accessed on McKesson’s Investor Relations website at investor.mckesson.com/financials/quarterly-results.

As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, February 4 at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson’s Investor Relations website, along with the company’s earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at investor.mckesson.com/events-and-presentations.

About McKesson Corporation

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights.

We routinely use our website, investor.mckesson.com, to post information that may be material to investors, such as business developments, earnings, and financial performance, as well as presentation materials and details for upcoming and past events.

Contacts

Investors

Investors@McKesson.com

Media Relations

MediaRelations@McKesson.com

Lōkahi Therapeutics Welcomes the Student Industry Fellows Program at the University of Georgia to the ai² Futures Lab™ Program




Lōkahi Therapeutics Welcomes the Student Industry Fellows Program at the University of Georgia to the ai² Futures Lab™ Program

LA JOLLA, Calif. & ATHENS, Ga.–(BUSINESS WIRE)–Lōkahi Therapeutics today announced the participation of the University of Georgia’s Student Industry Fellows Program in its ai² (actual intelligence) Futures Lab program for the Spring 2026 semester. Through this collaboration, University of Georgia students will engage in applied, real-world biotech and life sciences projects designed to bridge academic learning with industry execution.

The ai² Futures Lab program pairs multidisciplinary student teams with Lōkahi Therapeutics leadership to evaluate emerging assets, explore strategic pathways, and develop market-informed recommendations across discovery, development, and commercialization. The program emphasizes experiential learning, critical thinking, and practical exposure to decision-making within a pharmaceutical innovation environment.

“The ai² Futures Lab is designed to give students meaningful, hands-on experience at the intersection of science, strategy, and execution,” said Brian Peters, SVP, ai² Division, Lōkahi Therapeutics. “We are excited to welcome the Industry Fellows at the University of Georgia to the program this semester and look forward to the perspective, rigor, and curiosity they bring to real-world challenges.”

University of Georgia’s participation is supported through the Office of University Experiential Learning, reinforcing the institution’s commitment to applied education and industry engagement.

“This collaboration represents the type of experiential opportunity we strive to create for our students,” said Andrew H. Potter, Director, Office of University Experiential Learning and Head of the Student Industry Fellows Program, University of Georgia. “The ai² Futures Lab allows students to apply their academic training in a professional setting while gaining insight into the complexities of innovation within the life sciences sector.”

The partnership builds on Lōkahi Therapeutics’ broader mission to cultivate future leaders by exposing students to authentic industry problems and mentorship from experienced professionals.

“Programs like the ai² Futures Lab create a powerful learning environment by combining academic talent with industry context,” said Erik Emerson, CEO, Lōkahi Therapeutics. “We are proud to collaborate with the University of Georgia’s Student Industry Fellows Program and support students as they develop skills that will serve them well beyond the classroom.”

The ai² Futures Lab continues to expand its academic partnerships nationwide, connecting universities with Lōkahi Therapeutics’ innovation platform to advance both education and early-stage strategic thinking in the life sciences.

About Lōkahi Therapeutics

Lōkahi Therapeutics is focused on advancing innovative therapeutic opportunities through disciplined evaluation, strategic development, and collaborative discovery. Through initiatives like the ai² Futures Lab, Lōkahi integrates emerging talent into real-world problem-solving to help shape the future of healthcare. For more information, please visit us at www.lokahithera.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Apimeds undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Apimeds will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the company or its business or operations. Readers are cautioned that certain important factors may affect Apimeds’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect Apimeds’ results include, but are not limited to, the ability of Apimeds to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to Apimeds’ ability to advance its product candidate and successfully complete clinical trials; risks relating to its ability to hire and retain qualified personnel; and the additional risk factors described in Apimeds’ filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the SEC on April 15, 2025 (as amended on May 2, 2025).

Contacts

Media Contact:
Brian Peters

SVP, ai² Division

brian@lokahithera.com

CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings




CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

Company to host investor webcast and conference call on February 12 at 7 a.m. PT / 10 a.m. ET

Investor webcast will feature the clinical validation data and review commercial launch timeline

BRISBANE, Calif.–(BUSINESS WIRE)–CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, held February 4-7, 2026, in Salt Lake City, Utah.

The ACROBAT study is a prospective, multi-center, blinded clinical trial evaluating AlloHeme, CareDx’s AI-powered next-generation sequencing (NGS)-based peripheral blood test for monitoring relapse after allogeneic hematopoietic cell transplantation (HCT) in patients with hematologic malignancies. AlloHeme identifies cancer relapse ahead of traditional detection methods, potentially enabling timely clinical interventions. The ACROBAT study includes patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) monitored with AlloHeme for cancer relapse at 11 hematopoietic stem cell transplant centers across the U.S.

The oral presentation will feature the complete 24-month follow-up results, building upon 18-month interim results published in the conference abstract, available online here.

In addition, on February 12, 2025, CareDx will host an investor webcast and conference call to discuss the study findings and commercial launch timeline.

Tandem Presentation Details:

• Presentation ID 61: Acrobat Interim Results: Peripheral Blood-Based AlloHeme Test Enables Robust Relapse Surveillance in Post-HCT AML and MDS Patients
• Presenter: Dr. Ran Reshef, Professor of Medicine at Columbia University and Director of Translational Research, Blood and Marrow Transplantation Program at Herbert Irving Comprehensive Cancer Center
• Date & Time: Friday, February 6, 3:15 p.m. MT
• Location: Ballroom I, Salt Palace Convention Center

Investor Webcast Details:

• Presentation: AlloHeme Clinical Validation Data Review and Launch Timeline
• Date & Time: Wednesday, February 12, 7 a.m. PT / 10 a.m. ET
• The one-hour event will feature presentations by members of the CareDx’s leadership team and ACROBAT study site Principal Investigator, Dr. Ran Reshef.
• A live and archived webcast can be accessed on the Events & Presentations section of CareDx’s Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone, register here. Upon registering, a dial-in number and unique PIN will be provided.

About CareDx

CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. The Company’s integrated solutions include non‑invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics‑based information for transplant patients. For more information, please visit www.caredx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx including statements regarding the potential benefits and results that may be achieved with AlloHeme. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of AlloHeme are, risks that the findings in the ACROBAT study supporting the data may be inaccurate, general economic and market factors, and other risks discussed in CareDx’s filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, the Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed by CareDx with the SEC on November 4, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

CareDx, Inc.
Media

Natasha Moshirian Wagner

nwagner@CareDx.com

Investor Relations

Caroline Corner

investor@CareDx.com

Valo Health Appoints Karin Conde-Knape, Ph.D., as Chief Scientific Officer




Valo Health Appoints Karin Conde-Knape, Ph.D., as Chief Scientific Officer

Seasoned drug discovery leader will join Valo to further advance human-centric, AI-enabled drug discovery

LEXINGTON, Mass.–(BUSINESS WIRE)–#DrugDiscovery—Valo Health, Inc. (“Valo”), a company pioneering the use of human data and AI to accelerate drug discovery and development, today announced the appointment of Karin Conde-Knape, Ph.D., as Chief Scientific Officer (CSO). Dr. Conde-Knape brings more than two decades of expertise in drug development and translational science and a passion for patient-centric innovation.

Dr. Conde-Knape will join Valo following an extensive career at Novo Nordisk, where she had multiple roles including Senior Vice President of Early Development and Global Drug Discovery. She led research and early development across multiple therapeutic areas through internal and external innovation approaches. At Valo, she will oversee scientific strategy and execution, advancing a diverse portfolio of internal programs and global collaborations aimed at delivering transformative therapies for patients.

“Dr. Conde-Knape’s scientific leadership, passion for patient-centric innovation, and proven track record in drug discovery will be invaluable as we continue to scale our platform and deliver on our mission to transform drug discovery through AI-enabled human causal biology and predictive chemistry,” said Brian Alexander, MD, MPH, CEO of Valo. “We are thrilled to welcome her to the team during such an exciting time for the company and our industry.”

Dr. Conde-Knape’s appointment follows the planned retirement of Mike Graziano, Ph.D., Valo’s current CSO, who will transition to the role of Scientific Advisor. Dr. Graziano has been instrumental in advancing Valo’s science, platform and partnerships, leading the development and advancement of several internal and partnered programs.

“I have long admired Valo’s vision, ways of working, and bold approach to reimagining drug discovery,” said Dr. Conde-Knape. “By starting with human data and applying advanced analytical tools and techniques, we can better understand disease causality and design new drugs based on those learnings. I look forward to building on Valo’s momentum and partnering with the team to deliver more therapeutic breakthroughs for patients.”

Dr. Conde-Knape holds a Ph.D. in Nutritional Biochemistry from the University of Connecticut and has authored numerous publications in different areas of cardiometabolic disease biology and translational research. Prior to her role at Novo Nordisk, she spent several years at Hoffmann-La Roche in the Cardiovascular and Metabolism Discovery and early development areas, responsible for pharmacology teams as well as discovery and biomarker teams. She also led external innovation in Europe and Asia Pacific in Cardiovascular and Metabolism at Johnson & Johnson. Dr. Conde-Knape has been named one of the “Fiercest Women in Life Sciences” by Fierce Pharma, and one of the top 20 women breaking new ground in biopharma R&D by Endpoints News.

About Valo Health:

Valo is redefining drug discovery and development through its AI-enabled human causal biology and closed loop chemistry platforms. Valo uses AI to understand disease causality, identify patient subtypes across heterogeneous diseases, and pinpoint novel drug targets. The company validates targets using proprietary 3D engineered human tissue models that mimic mature human physiology and structure. The Company’s closed loop chemistry platform enables rapid development of potential molecules from trillions of starting points. Valo’s approach aims to identify more impactful drug targets and small molecule therapeutics, faster, and with greater precision than traditional R&D methods. Valo was founded by Flagship Pioneering in 2019. Follow us on LinkedIn and X.

Contacts

Media Contact:
Erin Smith

esmith@valohealth.com

RWS Launches New CNS Rater Training Service to Strengthen Data Quality in Clinical Trials




RWS Launches New CNS Rater Training Service to Strengthen Data Quality in Clinical Trials

Service ensures that clinicians are properly qualified, consistently trained and monitored throughout the life of a trial

MAIDENHEAD, England–(BUSINESS WIRE)–RWS (RWS.L), a global AI solutions company, announces the launch of a new rater training, certification and retraining service designed specifically to improve data quality, consistency and reliability in central nervous system (CNS) clinical trials.

The new service helps pharmaceutical sponsors and clinical research organizations (CROs) reduce one of the biggest risks in CNS studies: variability in how clinical raters assess patients. Even small differences in rater judgment can significantly affect trial data, timelines and outcomes.

RWS’s CNS rater training service ensures that clinicians involved in patient assessments are properly qualified, consistently trained and monitored throughout the life of a trial. The service is designed for complex, global CNS programs, where long study durations, multiple assessment points and geographically dispersed teams increase the risk of inconsistent data.

“CNS trials are uniquely sensitive to rater variability,” said Dan Herron, Global Vice President, Digital Health, RWS. “This service is designed to help sponsors reduce noise in the data, maintain consistency over time, and protect the scientific integrity of their CNS studies – without adding operational complexity.”

As CNS trials become more global, decentralized and digitally enabled, challenges such as inconsistent onboarding, certification drift and uneven use of assessment tools have become harder to manage. These risks are often compounded by the use of electronic Clinical Outcome Assessment (eCOA) technologies across different regions and languages.

RWS addresses these challenges by combining specialist CNS scientific expertise with structured training design and secure, scalable digital delivery. The service supports the full rater lifecycle and aligns with protocol requirements, regulatory expectations and modern eCOA workflows.

Service features

The CNS rater training service includes:

• Rater qualification and eligibility review, based on CNS-specific experience and protocol-defined criteria.
• Customized, indication- and scale-specific training, developed by experts in CNS clinician-reported and rater-administered outcome measures.
• Digital certification and remediation workflows, with automated tracking and certificate issuance.
• Ongoing retraining and refreshers to reduce rater drift during long or multi-phase studies.
• Centralized tracking and reporting to support monitoring, inspections and audits.

Training can be delivered globally and in multiple languages – supported by RWS’s eLearning development, localization, multimedia and linguistic validation capabilities. The service is technology-agnostic and can be used alongside any eCOA platform, ensuring consistent rater training regardless of how endpoint data is collected.

The launch expands RWS’s portfolio of CNS-focused solutions for life sciences organizations, supporting the clinical content and data lifecycle – from outcome assessment strategy and licensing to training, localization and AI-enabled workflows.

About us

RWS is a global AI solutions company empowering the world’s most trusted enterprise AI.

Our proprietary Cultural Intelligence Layer, powered by 250,000 data specialists, cultural and language experts and deep domain professionals, backed by 45+ patents, makes enterprise AI culturally fluent, contextually accurate and secure, ensuring every interaction reflects a brand’s tone, context and customer values.

Through our Generate, Transform and Protect segments, we deliver intelligent content, enterprise knowledge, large-scale localization and IP protection for global growth. Trusted by 80+ of the world’s top 100 brands, RWS provides the confidence, governance and expertise organizations need to deploy AI safely, responsibly and at scale.

Headquartered in the UK, RWS is listed on AIM.

More information: rws.com.

Contacts

RWS

Denis Davies

Corporate Communications

ddavies@rws.com
+44 1628 410105

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission




Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission

• The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults
• RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union^1-3

ZUG, Switzerland–(BUSINESS WIRE)–Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation aesthetic solutions that address evolving needs.

The filing is based on data from the robust, large-scale READY (REelabotulinumtoxin Aesthetic Development StudY) clinical trial program, which is composed of four phase III trials, enrolling more than 1,900 participants.^1-4 Results demonstrated that RelabotulinumtoxinA delivered a fast onset of action as early as Day 1 and sustained results for six months for both frown lines and crow’s feet.^1,2

RelabotulinumtoxinA (Relfydess™) has been approved in over 20 markets for the treatment of frown lines and crow’s feet, including in the European Union, the United Kingdom, Asia, and Australia. Regulatory applications are continuing to be submitted and assessed by additional authorities globally.

Galderma offers a range of neuromodulator solutions aiming to address every single injector and patient need, and has the heritage, expertise and capability needed to continue bringing this advanced solution to patients and healthcare professionals globally. Today, Galderma is well positioned to be the leader in all aspects of Injectable Aesthetics, having the in-house capabilities to discover, research, develop, manufacture, and market best-in-class products.

About RelabotulinumtoxinA

Pioneered by Galderma, RelabotulinumtoxinA is the first and only ready-to-use liquid neuromodulator manufactured with PEARL™ Technology, which is designed to preserve molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for glabellar lines and lateral canthal lines, giving patients a natural, revitalized look in a refined and well-tolerated formulation.^1-5 RelabotulinumtoxinA is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.^6,7 It was entirely created and manufactured by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market. RelabotulinumtoxinA has received a marketing authorization in numerous markets and is an investigational drug product in the U.S. Authorization conditions may vary internationally.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

1. Shridharani SM, et al. Efficacy and safety of RelabotulinumtoxinA, a new ready-to-use liquid formulation botulinum toxin: Results from the READY-1 double-blind, randomized, placebo-controlled phase 3 trial in glabellar lines. Aesthet Surg J. 2024;44(12):1330-1340. doi: 10.1093/asj/sjae131.
2. Ablon G, et al. Treatment of lateral canthal lines with RelabotulinumtoxinA, an investigational liquid botulinum toxin: clinical efficacy and safety results from the READY-2 phase 3 trial. Toxicon. 2024;237(1):107353. doi: 10.1026/j.toxicon.2024.107353.
3. Relfydess^®. EU Summary of Product Characteristics.
4. Galderma. Data on file. Clinical Study Report for Protocol 43QM1902: READY-3. Galderma Laboratories; 2021
5. Galderma. Data on file. Clinical Study Report for Protocol 43AM1903: READY-4. Galderma Laboratories; 2021
6. Sundberg AL and Stahl U. Relabotulinum toxin – a novel, high purity BoNT-A1 in liquid formulation. Presented at TOXINS; January 16-17, 2021; virtual meeting.
7. Do M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) – relabotulinumtoxinA. Presented at TOXINS; July 27-30, 2022; Louisiana, United States.

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com
+41 76 210 60 62

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com
+41 76 249 90 87

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com
+41 21 642 76 43

High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 2026




High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 2026

PARIS–(BUSINESS WIRE)–#AntiAging—Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation.

The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community.

Central to the academic discussions was Lorient’s “safety-first” philosophy for its premium HA filler range. By utilizing a sophisticated purification process that minimizes chemical cross-linking agents like BDDE, the brand proved its exceptional purity. This advanced manufacturing approach effectively reduces the risk of delayed inflammatory responses, a key concern for high-end practitioners. Dr. Jani van Loghem and Dr. Won Lee emphasized the filler’s low degree of modification, ensuring both a smooth injection experience and high biocompatibility. Additionally, its immediate reversibility with hyaluronidase provides an essential safety layer, further solidifying the trust of medical experts who prioritize patient welfare.

The spotlight also turned to ‘Lorient Element’, an innovative skin booster presented by Dr. Do Young Rhee. Engineered to overcome traditional limitations in pigment treatment, it features a potent blend of Tranexamic Acid, Ascorbic Acid, Niacinamide, and Glutathione at the maximum allowable concentrations. By utilizing a specialized hyaluronic acid delivery vehicle and low-molecular-weight particles under 500 Daltons, the formula ensures maximum penetration through the skin barrier. Clinical data showed that when combined with laser or microneedling treatments, Lorient Element improved pigmentation by over 60 percent in just four to five sessions.

Lorient stated that the successful session led by Dr. Jani van Loghem at IMCAS proves its advanced technology leads the global standard. Building on this success, Lorient is poised to accelerate strategic expansion into Europe, North America, and Southeast Asia, reinforcing its position as a visionary leader dedicated to setting the future of medical aesthetics.

Contacts

Lorient (Joonghun Pharmaceutical)

Jinwook Lee

+82-2-6929-0163

finest@mylorient.com

Tenacia Biopharmaceuticals and Golden Age Health Partner to Commercialize ZTALMY® for CDKL5 Deficiency Disorder in Mainland China




Tenacia Biopharmaceuticals and Golden Age Health Partner to Commercialize ZTALMY® for CDKL5 Deficiency Disorder in Mainland China

First-ever approved treatment for CDD in China now set for commercial launch through dedicated rare disease platform

SHANGHAI–(BUSINESS WIRE)–Tenacia Biopharmaceuticals (Shanghai) Co., Ltd. (“Tenacia“) and GOLDEN AGE HEALTH (SHANGHAI) CO., LTD., a subsidiary of Golden Age Health Pte. Ltd. (collectively, “GAH“) today announced a Commercialization Agreement granting GAH exclusive rights to commercialize ZTALMY^® (泽元安), the first and as of now only approved treatment for CDKL5 deficiency disorder (CDD) in Mainland China.

ZTALMY^® (ganaxolone oral suspension) was developed by Marinus and Tenacia obtains exclusive rights to develop and commercialize it in Greater China. In July 2024, the drug was approved by the National Medical Products Administration for treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.

Tenacia has partnered with GAH to leverage its comprehensive patient-focused commercialization platform—encompassing disease awareness, diagnosis support, market access, and patient affordability programs—to ensure this therapy reaches the families affected by this devastating rare epilepsy.

“Bringing the first approved therapy for CDKL5 deficiency disorder to patients in China represents exactly the type of mission-critical work Golden Age Health was built for,” said Chao (Brook) Wu, Chief Executive Officer of Golden Age Health (Shanghai). “We are honored to partner with Tenacia to ensure that children and families affected by CDD can access this breakthrough treatment as quickly as possible.”

Dr. Xiaoxiang Chen, Founder and CEO of Tenacia Biopharmaceuticals (Shanghai), said: “GAH’s proven expertise in rare disease commercialization and their commitment to patient access make them the ideal partner to bring ZTALMY^® to the patients who need it most in China. Together, we will work to maximize the impact of this important therapy.”

About CDKL5 Deficiency Disorder

CDKL5 deficiency disorder (CDD) is a rare developmental epileptic encephalopathy caused by mutations in the CDKL5 gene. Patients typically experience early-onset, treatment-resistant seizures, profound developmental delays, and motor impairments. CDD is included in China’s National Rare Disease Catalog, reflecting the urgent need for effective treatments for affected patients and their families.

About ZTALMY^® (ganaxolone oral suspension)

ZTALMY^® (ganaxolone oral suspension) is a neuroactive steroid GABA_A receptor positive allosteric modulator. The oral suspension formulation (110ml: 5.5g) is approved by China’s NMPA for the treatment of seizures associated with CDKL5 deficiency disorder in patients 2 years of age and older. It represents the first therapy specially approved for this indication in China.

About Golden Age Health

Golden Age Health is a specialty pharmaceutical company dedicated to redefining patient access to medicine across China, Asia-Pacific and MEA. Headquartered in Singapore, GAH pairs data-driven market-access expertise with deep medical-affairs and RWE capabilities to bring high-impact therapies to underserved populations.

About Tenacia Biopharmaceuticals

Founded in 2022 by Bain Capital, Tenacia is a commercial-stage biopharmaceutical company dedicated to developing innovative therapeutics for patients with underserved neurological disorders. Tenacia’s seasoned management team brings decades of drug development experience from both MNCs and biotechs. Their deep understanding of complex disease biology and insights into unmet patient needs enable Tenacia to create a highly efficient neuroscience R&D platform with a proven track record of advancing novel therapies. Empowered by its founder and strategic investor, Bain Capital – through significant initial investment, long-term commitment and extensive life science network – Tenacia is poised to become a leading neuroscience company in China and deliver substantial value to shareholders while upholding an unwavering commitment to the patients.

Forward-Looking Statements

This release contains forward-looking statements, including expectations regarding clinical development, regulatory matters and commercial launches. These statements involve risks and uncertainties that may cause actual outcomes to differ materially.

Contacts

Media & Investor Contacts
Golden Age Health
https://www.gahbioventures.com/
Media/IR: info@gahbioventures.com

Tenacia Biopharmaceuticals
官网：https://www.tenacia.com

AHF Receives Expedited Florida Hearing Opposing ADAP Reductions




AHF Receives Expedited Florida Hearing Opposing ADAP Reductions

Group sued Florida DOH over rules cutting lifesaving HIV/AIDS treatment for thousands

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Today, AIDS Healthcare Foundation (AHF) asked for and received an expedited hearing schedule in its legal efforts to block harmful changes to Florida’s AIDS Drug Assistance Plan (ADAP). It is estimated that 16,000 Floridians living with HIV/AIDS could lose access to life-saving medications and health insurance if these cuts go through. AHF and an ADAP recipient have brought an administrative suit to block these changes.

The cuts are scheduled to begin March 1. Under normal administrative procedures and timing rules, a decision on AHF’s case would not be reached until after March 1, making it too late to stop the cuts from being implemented. However, AHF asked for an expedited hearing schedule to get a decision before the cuts go into effect. The administrative law judge (ALJ), understanding the dire health impacts on these 16,000 should the cuts occur, agreed to move the case along more quickly.

The case will be heard on February 18, and the ALJ intends to issue a ruling on February 27. AHF is heartened that the ALJ understands the potential impacts these cuts represent and agreed to resolve this matter before the cuts would go into effect. If AHF is successful, these cuts will be prevented from occurring on March 1.

In its petition, filed Tuesday in Tallahassee, AHF asserted the Florida’s Department of Health illegally changed rules regarding income eligibility thresholds for its AIDS Drug Assistance Program (ADAP), without having gone through the mandatory rulemaking process. AHF’s petition was filed Tuesday with Florida’s Division of Administrative Hearings and prepared by Panza, Maurer & Maynard, P.A. of Tallahassee, Florida.

AIDS Healthcare Foundation (AHF), the world’s largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 2.8 million individuals across 50 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. In January 2025, AHF received the MLK, Jr. Social Justice Award, The King Center’s highest recognition for an organization leading work in the social justice arena. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, and follow us on Instagram, Twitter, and TikTok.

Contacts

Media Contacts:
W. Imara Canady, National Director, Communications & Community Engagement, AHF

Cell: 770-940-6555/Email: imara.canady@ahf.org

Ged Kenslea, AHF Senior Communications Director

gedk@aidshealth.org
(323) 791-5526

The Cannabist Company Enters Into Forbearance Agreement With Senior Secured Noteholders




The Cannabist Company Enters Into Forbearance Agreement With Senior Secured Noteholders

CHELMSFORD, Mass.–(BUSINESS WIRE)–The Cannabist Company Holdings Inc. (Cboe CA: CBST) (OTCQB: CBSTF) (“The Cannabist Company” or “the Company”), one of the most experienced cultivators, manufacturers and retailers of cannabis products in the United States, today announced that it has entered into a forbearance agreement (the “Forbearance Agreement”), with an ad hoc group of noteholders (the “Forbearing Noteholders”) of the Company’s 9.25% Senior Secured Notes due December 31, 2028 (the “9.25% Senior Secured Notes”) and the 9.00% Senior Secured Convertible Notes due December 31, 2028 (the “9.00% Senior Secured Convertible Notes” and together with the 9.25% Senior Secured Notes, the “Notes”). The Forbearing Noteholders collectively hold more than 75% of the aggregate principal amount of Notes outstanding.

On December 31, 2025, the Company elected not to make the interest payments due on the Notes (the “December 31 Interest Payments”) under the amended and restated indenture, as supplemented, governing the Notes (the “Indenture”) to enhance its short-term financial flexibility and preserve liquidity as it continues to evaluate strategic alternatives following the recent announcement of the sale of its Virginia assets to an affiliate of Millstreet Credit Fund LP. The failure to make the December 31 Interest Payments on the due date did not constitute an event of default under the Indenture. However, the non-payment of the December 31 Interest Payments during the 30-day grace period under the Indenture constitutes an event of default.

During the grace period, the Company and the Forbearing Noteholders discussed potential strategies and options to address the Company’s liquidity needs, including potential additional asset sales or other strategic, financial or restructuring transactions or proceedings, which resulted in entering into the Forbearance Agreement.

Pursuant to the Forbearance Agreement, and subject to the terms and conditions set forth therein, the Forbearing Noteholders agreed to forbear from exercising any of their rights and remedies under the Indenture and applicable law until February 17, 2026 as a result of the Company’s failure to make the December 31 Interest Payments. The Company, its advisors and the advisors to the Forbearing Noteholders continue to discuss options to address the Company’s liquidity needs, however, there can be no assurances an agreement will be reached, or an extension of the Forbearance Agreement will be entered into prior to February 17, 2026.

About The Cannabist Company (f/k/a Columbia Care)

The Cannabist Company, formerly known as Columbia Care, is one of the most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 12 U.S. jurisdictions. The Company operates 77 facilities including 61 dispensaries and 16 cultivation and manufacturing facilities, including those under development. Columbia Care, now The Cannabist Company, is one of the original multi-state providers of cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the Company launched Cannabist, its retail brand, creating a national dispensary network that leverages proprietary technology platforms. The Company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including dreamt, Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber. For more information, please visit www.cannabistcompany.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 and corresponding Canadian securities laws. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding use of proceeds, future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, as well as the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2024, its quarterly report on Form 10-Q for the quarter ended September 30, 2025, and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov and in Canada on SEDAR+, available at www.sedarplus.ca. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

Contacts

Investor & Media Contact
Lee Ann Evans

SVP, Capital Markets & Communications

investor@cannabistcompany.com